Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Blinklab Limited ( (AU:BB1) ) is now available.
BlinkLab has secured a significant validation of its technology with the publication of a peer-reviewed paper in Autism Research, the official journal of the International Society for Autism Research and a leading Q1 title in the field. The study, conducted on a large multi-centre cohort of 536 children in Morocco, demonstrates that BlinkLab’s smartphone-based platform can reliably identify distinct sensorimotor profiles associated with autism using objective, reflex-based measures rather than traditional subjective clinical observation. The publication is described by the company as a key milestone that materially strengthens its clinical evidence base, bolstering its regulatory strategy and supporting the case for future clinical adoption of its technology, while a follow-up paper is being prepared to detail the diagnostic and predictive performance of the company’s machine learning models.
More about Blinklab Limited
BlinkLab Limited is an ASX-listed company developing smartphone-based neurobehavioural assessment technology aimed at improving the diagnosis and understanding of neurodevelopmental disorders, particularly autism. Its core platform uses standard smartphones to capture objective measures such as facial reflexes, startle responses, eye and eyelid movements, postural stability, and vocal and behavioural responses in at-home environments, positioning the company at the intersection of digital health, neuroscience and clinical diagnostics.
Average Trading Volume: 375,644
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$103.9M
For detailed information about BB1 stock, go to TipRanks’ Stock Analysis page.